Directorate Change

GlaxoSmithKline plc announces changes to its Board

GlaxoSmithKline plc (the 'Company') today announces that Sir Christopher Gent will step down as Chairman of GSK at the Company's Annual General Meeting on 7 May 2015 ('AGM'). He will be succeeded by Sir Philip Hampton with effect from the end of the AGM.

Sir Philip joined GSK's Board as an independent Non-Executive Director on 1 January 2015, and will become Deputy Chairman on 1 April 2015. Sir Philip chairs the Company's Nominations Committee. He will remain Chairman of RBS until 31 August 2015.

In addition, Tom de Swaan, independent Non Executive Director, is not seeking re-election to the Board at the AGM. He has been a Board member for 9 years and is currently Chairman of the Remuneration Committee and a member of the Audit & Risk Committee (of which he was previously Chairman), and the Nominations Committee. A successor for Mr de Swaan as Chairman of the Remuneration Committee will be announced in due course.

Jing Ulrich has decided not to stand for re-election to the Board at the AGM.

V A Whyte

Company Secretary

26 February 2015

Notes

With effect from the end of the Company's AGM on 7 May 2015, the composition of the Board of GSK will be as follows:

Sir Philip Hampton Non-Executive Chairman

Sir Deryck Maughan Senior Independent Non-Executive Director

Sir Andrew Witty Chief Executive Officer

Simon Dingemans Chief Financial Officer

Dr Moncef Slaoui Executive Director, Chairman, Global Vaccines

Professor Sir Roy Anderson Independent Non-Executive Director

Dr Stephanie Burns Independent Non-Executive Director

Stacey Cartwright Independent Non-Executive Director

Lynn Elsenhans Independent Non-Executive Director

Judy Lewent Independent Non-Executive Director

Dr Daniel Podolsky Independent Non-Executive Director

Urs Rohner Independent Non-Executive Director

Hans Wijers Independent Non-Executive Director